Y. Cheng
L. Zhang
J. Hu
D. Wang
C. Hu
J. Zhou
L. Wu
L. Cao
J. Liu
H. Zhang
H. Sun
Z. Wang
H. Gao
Y. Sun
B. Li
L. Paz-Ares
Department of Respiration, Anhui Provincial Hospital, Zhengwu District, Hefei/CN
Department of Respiratory Diseases, the First Affiliated Hospital of Zhejiang University, Hangzhou/CN
Respiratory Medicine Department, Peking Union Medical College Hospital, Dongcheng District, Beijing/CN
Department of Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian/CN
Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Haidian District, Beijing/CN
Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
Merck & Co., Inc., Kenilworth, NJ
Hospital Universitario, Madrid/ES
Department of Oncology, Chongqing Cancer Hospital, Chongqing/CN
Msd China, Shanghai/CN
Msd China, Beijing/CN
Department of Pulmonary Medicine, Zhongshan Hospital Fudan University, Shanghai/CN
Department of Medical Oncology, Jilin Cancer Hospital, Chaoyang Borough, Changchun/CN
Department Ii of Thoracic Medicine, Hunan Cancer Hospital, Changsha/CN
Department of Pulmonary Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing/CN
Department of Respirology and Critical Care Medicine, Xiangya Hospital Central South University, Changsha, Hunan/CN
Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
China
United States
United Kingdom
Spain
N/A
Oncology (ONC)
Non Small Cell Lung cancer
Programmed death-ligand 1
Tissue polypeptide-specific antigen
Pembrolizumab
Carboplatin
Paclitaxel
N/A
Randomized
Placebo Control
Cross Over
Double Blind/Blinded
N/A
NCT03875092
N/A
N/A